These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 21293087)
1. A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension. Weir MR; Punzi HA; Flack JM; Stoakes KA; Chavanu KJ; Li W; Dubiel R Postgrad Med; 2011 Jan; 123(1):80-7. PubMed ID: 21293087 [TBL] [Abstract][Full Text] [Related]
2. Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension. Flack JM; Graff A; Li W; Chavanu KJ Postgrad Med; 2012 May; 124(3):59-70. PubMed ID: 22691900 [TBL] [Abstract][Full Text] [Related]
3. Efficacy/safety of olmesartan medoxomil versus losartan potassium in naïve versus previously treated subjects with hypertension. Punzi HA; Lewin A; Li W; Chavanu KJ Adv Ther; 2012 Jun; 29(6):524-37. PubMed ID: 22763801 [TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension]. Zhu JR; Cai NS; Fan WH; Zhu DL; He B; Wu ZG; Ke YN; Guo JX; Ma H; Huang J; Li XL; Chen YZ Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):877-81. PubMed ID: 17217710 [TBL] [Abstract][Full Text] [Related]
5. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Oparil S; Melino M; Lee J; Fernandez V; Heyrman R Clin Ther; 2010 Jul; 32(7):1252-69. PubMed ID: 20678674 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy. Hsueh WA; Shojaee A; Maa JF; Neutel JM Curr Med Res Opin; 2012 Nov; 28(11):1809-18. PubMed ID: 23072496 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study. Punzi HA Ther Adv Cardiovasc Dis; 2014 Feb; 8(1):12-21. PubMed ID: 24492985 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Chrysant SG; Weber MA; Wang AC; Hinman DJ Am J Hypertens; 2004 Mar; 17(3):252-9. PubMed ID: 15001200 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy. Neutel J; Shojaee A; Maa JF Adv Ther; 2012 Jun; 29(6):508-23. PubMed ID: 22773358 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension. Germino FW; Neutel JM; Dubiel R; Maa JF; Chavanu KJ Am J Cardiovasc Drugs; 2012 Oct; 12(5):325-33. PubMed ID: 22920048 [TBL] [Abstract][Full Text] [Related]
11. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Chrysant SG; Melino M; Karki S; Lee J; Heyrman R Clin Ther; 2008 Apr; 30(4):587-604. PubMed ID: 18498909 [TBL] [Abstract][Full Text] [Related]
12. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. Oparil S; Lee J; Karki S; Melino M J Cardiovasc Pharmacol; 2009 Nov; 54(5):427-36. PubMed ID: 19730391 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Punzi H; Neutel JM; Kereiakes DJ; Shojaee A; Waverczak WF; Dubiel R; Maa JF Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):209-21. PubMed ID: 20519261 [TBL] [Abstract][Full Text] [Related]
14. Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. Rump LC; Girerd X; Sellin L; Stegbauer J J Hum Hypertens; 2011 Sep; 25(9):565-74. PubMed ID: 21107435 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of amlodipine/olmesartan medoxomil ± hydrochlorothiazide in patients aged ≥ 65 or < 65 years with uncontrolled hypertension on prior monotherapy. Weir MR; Shojaee A; Maa JF Postgrad Med; 2013 Mar; 125(2):124-34. PubMed ID: 23816778 [TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study. Chrysant SG Clin Drug Investig; 2010; 30(7):473-82. PubMed ID: 20528002 [TBL] [Abstract][Full Text] [Related]
17. Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. Ram CV; Sachson R; Littlejohn T; Qian C; Shojaee A; Stoakes KA; Neutel JM Am J Cardiol; 2011 May; 107(9):1346-52. PubMed ID: 21497211 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study. Fogari R; Taddei S; Holm-Bentzen M; Baszak J; Melani L; Schumacher K Clin Drug Investig; 2010; 30(9):581-97. PubMed ID: 20593911 [TBL] [Abstract][Full Text] [Related]
19. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study. Shimada K; Ogihara T; Saruta T; Kuramoto K; Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH; Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]